Business Description
Context Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US21077P1084
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1806.25 | |||||
Equity-to-Asset | 0.74 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | -16.1 | |||||
3-Year FCF Growth Rate | -135.4 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 48.63 | |||||
9-Day RSI | 51.34 | |||||
14-Day RSI | 53.33 | |||||
6-1 Month Momentum % | 41.3 | |||||
12-1 Month Momentum % | 147.62 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.83 | |||||
Quick Ratio | 3.83 | |||||
Cash Ratio | 3.45 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.1 | |||||
Shareholder Yield % | 0.32 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -101.76 | |||||
ROA % | -87.62 | |||||
ROIC % | -3812.65 | |||||
ROC (Joel Greenblatt) % | -63634.52 | |||||
ROCE % | -106.46 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.84 | |||||
Price-to-Tangible-Book | 1.8 | |||||
EV-to-EBIT | 0.15 | |||||
EV-to-Forward-EBIT | -1.23 | |||||
EV-to-EBITDA | 0.15 | |||||
EV-to-Forward-EBITDA | -1.35 | |||||
EV-to-FCF | 0.15 | |||||
Price-to-Net-Current-Asset-Value | 1.8 | |||||
Price-to-Net-Cash | 2.07 | |||||
Earnings Yield (Greenblatt) % | 684.21 | |||||
FCF Yield % | -98.13 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Context Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -1.392 | ||
Beta | 0 | ||
Volatility % | 102.26 | ||
14-Day RSI | 53.33 | ||
14-Day ATR (€) | 0.049745 | ||
20-Day SMA (€) | 1.2365 | ||
12-1 Month Momentum % | 147.62 | ||
52-Week Range (€) | 0.42 - 1.44 | ||
Shares Outstanding (Mil) | 15.97 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Context Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Context Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Context Therapeutics Inc Frequently Asked Questions
What is Context Therapeutics Inc(FRA:6K9)'s stock price today?
When is next earnings date of Context Therapeutics Inc(FRA:6K9)?
Does Context Therapeutics Inc(FRA:6K9) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |